TipRanks (Tue, 7-Jul 12:50 PM ET)
Dyadic's C1 Platform Secures Global Backing as Rapid Biologics Manufacturing Gains Traction
Market Chameleon (Tue, 7-Jul 7:06 AM ET)
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
Globe Newswire (Tue, 7-Jul 7:25 AM ET)
Major Stakeholder Shakes Up Dyadic International With Notable Stock Sale
TipRanks (Mon, 6-Jul 10:02 PM ET)
Dyadic Expands IP Protection and Business Development Activities in Japan
Globe Newswire (Mon, 29-Jun 7:25 AM ET)
Globe Newswire (Mon, 15-Jun 7:25 AM ET)
Globe Newswire (Thu, 28-May 7:25 AM ET)
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Globe Newswire (Thu, 21-May 4:05 PM ET)
Globe Newswire (Thu, 21-May 3:45 PM ET)
Sidoti Events, LLC's May Micro-Cap Virtual Conference
ACCESS Newswire (Wed, 20-May 7:30 AM ET)
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Dyadic International trades on the NASDAQ stock market under the symbol DYAI.
As of July 8, 2026, DYAI stock price declined to $1.01 with 89,536 million shares trading.
DYAI has a beta of 2.02, meaning it tends to be more sensitive to market movements. DYAI has a correlation of 0.11 to the broad based SPY ETF.
DYAI has a market cap of $36.80 million. This is considered a Sub-Micro Cap stock.
Last quarter Dyadic International reported $1 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $124,120 and missed earnings estimates by -$.02.
In the last 3 years, DYAI traded as high as $2.67 and as low as $.65.
The top ETF exchange traded funds that DYAI belongs to (by Net Assets): VTI, VXF.
DYAI has underperformed the market in the last year with a return of +10.3%, while SPY returned +21.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DYAI shares. However, DYAI has outperformed the market in the last 3 month and 2 week periods, returning +14.8% and +25.3%, while SPY returned +13.1% and +1.4%, respectively. This indicates DYAI has been having a stronger performance recently.
DYAI support price is $.98 and resistance is $1.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DYAI shares will trade within this expected range on the day.